# reload+after+2024-01-22 19:40:07.075549
address1§Queen Mary BioEnterprises Innovation Ctr
address2§42 New Road
city§London
zip§E1 2AX
country§United Kingdom
phone§44 20 7183 1499
website§https://www.poolbegpharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Jeremy  Skillington Ph.D.', 'age': 52, 'title': 'CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 310000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Ian  O'Connell", 'age': 36, 'title': 'CFO & Director', 'yearBorn': 1987, 'fiscalYear': 2022, 'totalPay': 220000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Carol  Dalton', 'title': 'Vice President of Investor Relations & Public Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  McEvoy', 'title': 'Senior Vice President & Chief Legal Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David James Allmond', 'age': 53, 'title': 'Chief Business Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Salim Gulamabbas Hamir F.C.A.', 'title': 'Company Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ross  Crockett', 'title': 'Group Financial Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.261
currency§GBp
forwardEps§-1.19
exchange§LSE
quoteType§EQUITY
shortName§POOLBEG PHARMA PLC ORD 0.02P
longName§Poolbeg Pharma PLC
firstTradeDateEpochUtc§1626678000
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§0b9dbdfc-8b00-3ca0-8933-427bab480ba7
recommendationMean§2.0
recommendationKey§buy
quickRatio§27.728
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
